Search

Displaying results 3341 - 3350 of 10000 in total
  1. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.

  2. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  3. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    Susoctocog alfa is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker. … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.

  4. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

    Products: Xigris (5mg/vial)
  6. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.

  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  8. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    It was withdrawn from the market in the United Kingdom in 1979.

  9. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    was 8.3 months. … [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.

    Synonyms: (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol